{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'A manuscript will be progressed for publication in the scientific literature if the', 'results provide important scientific or medical knowledge.', 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic', 'CRF unless transmitted to the sponsor or designee electronically (e.g.,', 'laboratory data). The investigator is responsible for verifying that data entries', 'are accurate and correct by physically or electronically signing the CRF.', 'The investigator must maintain accurate documentation (source data) that', 'supports the information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', 'The sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that', 'data entered into the CRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of participants', 'are being protected; and that the study is being conducted in accordance with the', 'currently approved protocol and any other study agreements, ICH GCP, and all', 'applicable regulatory requirements.', 'Records and documents, including signed ICF, pertaining to the conduct of this', 'study must be retained by the investigator for 25 years from the issue of the final', 'Clinical Study Report (CSR)/ equivalent summary or as locally agreed unless', 'local regulations or institutional policies require a longer retention period. No', 'records may be destroyed during the retention period without the written', 'approval of the sponsor. No records may be transferred to another location or', 'party without written notification to the sponsor.', 'Source Documents', 'Source documents provide evidence for the existence of the participant and', 'substantiate the integrity of the data collected. Source documents are filed at the', \"investigator's site.\", 'Data entered in the eCRF that are transcribed from source documents must be', 'consistent with the source documents or the discrepancies must be explained.', 'The investigator may need to request previous medical records or transfer', 'records, depending on the study. Also, current medical records must be', 'available.', 'Definition of what constitutes source data can be found in SRM.', '114']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Study and Site Closure', 'GSK or its designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of GSK. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study', 'supplies have been collected and a study-site closure visit has been performed.', 'The investigator may initiate study-site closure at any time, provided there is reasonable', 'cause and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the sponsor or investigator may include', 'but are not limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', \"IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines\", 'Inadequate recruitment of participants by the investigator', 'Discontinuation of further study treatment development', '115']['2017N330177_04', 'CONFIDENTIAL', '205678', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', 'Definition of AE', 'AE Definition', 'An AE is any untoward medical occurrence in a clinical study participant, temporally', 'associated with the use of a study treatment, whether or not considered related to the', 'study treatment.', 'Note: An AE can therefore be any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally', 'associated with the use of a study treatment.', 'Events Meeting the AE Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis)', 'or other safety assessments (e.g., ECG, radiological scans, vital signs', 'measurements), including those that worsen from baseline, considered clinically', 'significant in the medical and scientific judgment of the investigator (i.e., not related', 'to progression of underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an', 'increase in frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study treatment administration even', 'though it may have been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study', 'treatment or a concomitant medication. Overdose per se will not be reported as an', 'AE/SAE unless it is an intentional overdose taken with possible suicidal/self-', 'harming intent. Such overdoses must be reported regardless of sequelae.', '\"Lack of efficacy\" or \"failure of expected pharmacological action\" per se will not be', 'reported as an AE or SAE. Such instances will be captured in the efficacy assessments.', 'However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy', 'will be reported as AE or SAE if they fulfill the definition of an AE or SAE.', 'Events NOT Meeting the AE Definition', 'Any clinically significant abnormal laboratory findings or other abnormal safety', 'assessments which are associated with the underlying disease, unless judged by the', \"investigator to be more severe than expected for the participant's condition.\", 'The disease/disorder being studied or expected progression, signs, or symptoms of', 'the disease/disorder being studied, unless more severe than expected for the', '116']\n\n###\n\n", "completion": "END"}